Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

医学 德诺苏马布 唑来膦酸 前列腺癌 临床终点 内科学 肿瘤科 安慰剂 泌尿科 癌症 随机对照试验 骨质疏松症 病理 替代医学
作者
Karim Fizazi,Michael A. Carducci,Matthew R. Smith,Ronaldo Damião,Janet E. Brown,Lawrence I. Karsh,Piotr Milecki,Neal D. Shore,Michael Rader,Huei Wang,Qi Jiang,Sylvia Tadros,Roger Dansey,Carsten Goessl
出处
期刊:The Lancet [Elsevier BV]
卷期号:377 (9768): 813-822 被引量:1889
标识
DOI:10.1016/s0140-6736(10)62344-6
摘要

Bone metastases are a major burden in men with advanced prostate cancer. We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic acid for prevention of skeletal-related events in men with bone metastases from castration-resistant prostate cancer.In this phase 3 study, men with castration-resistant prostate cancer and no previous exposure to intravenous bisphosphonate were enrolled from 342 centres in 39 countries. An interactive voice response system was used to assign patients (1:1 ratio), according to a computer-generated randomisation sequence, to receive 120 mg subcutaneous denosumab plus intravenous placebo, or 4 mg intravenous zoledronic acid plus subcutaneous placebo, every 4 weeks until the primary analysis cutoff date. Randomisation was stratified by previous skeletal-related event, prostate-specific antigen concentration, and chemotherapy for prostate cancer within 6 weeks before randomisation. Supplemental calcium and vitamin D were strongly recommended. Patients, study staff, and investigators were masked to treatment assignment. The primary endpoint was time to first on-study skeletal-related event (pathological fracture, radiation therapy, surgery to bone, or spinal cord compression), and was assessed for non-inferiority. The same outcome was further assessed for superiority as a secondary endpoint. Efficacy analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00321620, and has been completed.1904 patients were randomised, of whom 950 assigned to denosumab and 951 assigned to receive zoledronic acid were eligible for the efficacy analysis. Median duration on study at primary analysis cutoff date was 12·2 months (IQR 5·9-18·5) for patients on denosumab and 11·2 months (IQR 5·6-17·4) for those on zoledronic acid. Median time to first on-study skeletal-related event was 20·7 months (95% CI 18·8-24·9) with denosumab compared with 17·1 months (15·0-19·4) with zoledronic acid (hazard ratio 0·82, 95% CI 0·71-0·95; p = 0·0002 for non-inferiority; p = 0·008 for superiority). Adverse events were recorded in 916 patients (97%) on denosumab and 918 patients (97%) on zoledronic acid, and serious adverse events were recorded in 594 patients (63%) on denosumab and 568 patients (60%) on zoledronic acid. More events of hypocalcaemia occurred in the denosumab group (121 [13%]) than in the zoledronic acid group (55 [6%]; p<0·0001). Osteonecrosis of the jaw occurred infrequently (22 [2%] vs 12 [1%]; p = 0·09).Denosumab was better than zoledronic acid for prevention of skeletal-related events, and potentially represents a novel treatment option in men with bone metastases from castration-resistant prostate cancer.Amgen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
现代小丸子完成签到 ,获得积分10
1秒前
缺水哥完成签到,获得积分10
1秒前
缺水哥发布了新的文献求助10
4秒前
1234发布了新的文献求助10
4秒前
1762120完成签到,获得积分10
4秒前
ZR关闭了ZR文献求助
6秒前
卖萌的秋田完成签到,获得积分10
6秒前
热情铭完成签到 ,获得积分10
7秒前
完美麦片完成签到,获得积分10
12秒前
lll完成签到,获得积分10
13秒前
务实鞅完成签到 ,获得积分10
14秒前
量子星尘发布了新的文献求助10
19秒前
mawenyu完成签到,获得积分10
20秒前
17完成签到,获得积分20
20秒前
高大的水壶完成签到,获得积分10
21秒前
英俊的铭应助wellyou采纳,获得10
23秒前
风中的向卉完成签到 ,获得积分10
26秒前
Mp4完成签到 ,获得积分10
26秒前
凌兰完成签到 ,获得积分10
26秒前
plain完成签到,获得积分10
27秒前
陌上花开完成签到,获得积分10
28秒前
29秒前
fg2477完成签到,获得积分10
30秒前
忙碌的数学人完成签到,获得积分10
30秒前
情怀应助Engen采纳,获得10
30秒前
HJJHJH完成签到,获得积分10
32秒前
Bob发布了新的文献求助10
33秒前
34秒前
35秒前
HJJHJH发布了新的文献求助50
36秒前
JW完成签到,获得积分10
36秒前
wanci应助张参采纳,获得10
37秒前
谦让的西装完成签到 ,获得积分10
38秒前
李演员完成签到,获得积分10
39秒前
fei菲飞完成签到,获得积分10
39秒前
41秒前
Zhaowx完成签到,获得积分10
41秒前
Theprisoners完成签到,获得积分0
41秒前
木子发布了新的文献求助30
41秒前
41秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022